Humana (HUM) Stock Forecast & Price Target
$50.03B
Market Cap
38.95
P/E
45.49
Forward P/E
35
Score
HUM price $416.64 +4.77 +1.16%
Stocklytics score rationale: value 40, quality 36, growth 29.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 54405000000 | 53800000000 | 56944000000 | 64933000000 | 77191000000 | 83648000000 | 92922000000 | 106440000000 | 117811000000 | 129664000000 |
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government…
Consensus Buy from 29 analysts. Average price target $469.89, +12.8% versus the current price. Low $300.00. High $596.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $469.89 for Humana (HUM), 13.6% above the current price of $413.70. Of 29 analysts covering the stock, 16 rate it Buy or Strong Buy, 12 Hold, and 1 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $300.00 |
|---|---|
| Average | $469.89 |
| High | $596.00 |
The average is 13.6% above the current price of $413.70.
Of 29 analysts, 16 rate Humana Buy or Strong Buy, 12 Hold, and 1 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS $9.16, revenue $162.56 billion. 2027, EPS $16.96, revenue $167.79 billion.
The Stocklytics Score for HUM is 35 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
$469.89 average, with a published range of $300.00 to $596.00.
The consensus is Buy from 29 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is $9.16. The average revenue estimate is $162.56 billion.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: Humana · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$50.03B
Market Cap
38.95
P/E
45.49
Forward P/E
35
Score